US Patent

US8614178 — Pharmaceutical composition for treatment of dry eye syndrome

Formulation · Assigned to Novaliq GmbH · Expires 2030-12-13 · 5y remaining

Vulnerability score 56/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects novel pharmaceutical compositions for treating dry eye syndrome that include semifluorinated alkanes and macrolide immunosuppressants.

USPTO Abstract

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.

Drugs covered by this patent

Patent Metadata

Patent number
US8614178
Jurisdiction
US
Classification
Formulation
Expires
2030-12-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Novaliq GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.